Inactive Instrument

Ariad Pharmaceuticals, Inc. Stock

Stocks

End-of-day quote Nasdaq
- ^USD	-

10/01/17	Takeda Pharmaceutical : Japan's Takeda ready for fresh acquisitions after $5.2 billion Ariad deal	RE
02/06/14	Dai ichi Life Insurance : U.S. futures flat with Dow, S&P at record levels	RE

10/01/17	Takeda Pharmaceutical : Japan's Takeda ready for fresh acquisitions after $5.2 billion Ariad deal	RE
02/06/14	Dai ichi Life Insurance : U.S. futures flat with Dow, S&P at record levels	RE
20/01/14	Insight: Shorts set to pounce as stocks seen pricey, Fed pulls back	RE
18/12/13	Prosensa Holding NV : Investment risks of fast-tracking biotech drugs become apparent	RE
02/07/13	Onyx Pharmaceuticals, Inc. : Pfizer, Novartis may join Amgen in bidding for Onyx: sources	RE
24/04/12	Actelion Ltd : New Amgen CEO must win investors with payouts, deals	RE

06/02/17	Ariad Pharmaceuticals : Announces Submission of Marketing Authorization Application for Brigatinib to the European Medicines Agency	BU
03/02/17	Ariad Pharmaceuticals : Enters into Definitive Agreement to Be Acquired by Takeda for $5.2 Billion	PU
03/02/17	Ariad Pharmaceuticals : Takeda to Acquire ARIAD Pharmaceuticals, Inc.	PU
18/01/17	Ariad Pharmaceuticals : Acquisition May Not Be in the Best Interests of ARIA Shareholders	PR
13/01/17	Brower Piven Commences An Investigation Into The Proposed Sale Of ARIAD Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information	BU

09/01/17	Takeda Pharmaceutical : rachète l'américain Ariad pour 5,2 milliards de dollars
09/01/17	Takeda rachète l'américain Ariad pour $5,2 mds
10/05/16	Ariad Pharmaceuticals : Incyte et ARIAD annoncent un accord dans le cadre duquel Incyte rachètera les opérations européennes d'ARIAD et vendra sous licence Iclusig® (ponatinib) en Europe
09/05/16	Ariad Pharmaceuticals : Incyte und ARIAD geben Vereinbarung zur Übernahme des europäischen Geschäfts von ARIAD durch Incyte und die Einlizenzierung von Iclusig® (Ponatinib) in Europa bekannt
08/12/15	Ariad Pharmaceuticals : annonce le début de l’essai randomisé de phase III OPTIC-2L comparant le ponatinib au nilotinib dans le traitement de deuxième ligne de patients atteints de leucémie myéloïde chronique en phase chronique

Manager	Title	Age	Since
Teresa Marie Bitetti PSD	President	63	-
Mario Damo TRE	Treasurer	-	-
Jason E. Baranski SEC	Corporate Secretary	-	-

Director	Title	Age	Since
Teresa Marie Bitetti BRD	Director/Board Member	63	-
Mario Damo BRD	Director/Board Member	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	-0.73%	+12.52%	+74.33%	+102.34%	70.51B
ARGENX SE	+1.60%	+4.53%	+37.56%	+67.36%	54.05B
INSMED INCORPORATED	-0.22%	+33.95%	+17.18%	+489.75%	28.95B
WUXI BIOLOGICS (CAYMAN) INC.	-0.61%	+12.95%	+53.77%	+5.42%	24.05B
BIONTECH SE	-0.06%	+1.52%	-15.12%	-13.26%	23.31B
PHARMAESSENTIA CORPORATION	-1.37%	+18.52%	+255.24%	+464.53%	18.67B
GENMAB A/S	+2.21%	+8.47%	+50.06%	-20.09%	18.37B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	0.00%	+9.69%	+31.01%	+584.59%	16.1B
EXELIXIS, INC.	-1.85%	-10.04%	+34.67%	+134.11%	12.72B
Average	-0.11%	+9.21%	+59.85%	+201.64%	29.64B
Weighted average by Cap.	+0.02%	+10.12%	+57.49%	+166.00%

Employees

Sector